AbCellera Biologics ABCL
NASDAQ ABCL
$13.92 +1.22 (+9.61%)
At close: Sep 28, 2026 · 4:00 PM EDT

AbCellera Biologics (ABCL) EBITDA Margin (2020 - 2026)

Updated

AbCellera Biologics' EBITDA Margin was -1376.44% in Q2 2026, down 1118.57 percentage points from -257.88% a year earlier and down 766.93 percentage points from the prior quarter.

Analysis

AbCellera Biologics (ABCL) EBITDA Margin (2020 - 2026) Analysis & Trends

On a trailing twelve-month basis, AbCellera Biologics' EBITDA Margin was -302.19% through Jun 30, 2026, up 361.99 percentage points year-over-year; for FY2025, it was -259.47%, up 517.13 percentage points from FY2024.

  • EBITDA Margin shows a five-year change of -328.46 percentage points (FY2020 to FY2025).
  • In earlier years, EBITDA Margin was -776.60% in FY2024 (-217.05 pp), -559.55% in FY2023 (-609.90 pp), 50.35% in FY2022 (-7.99 pp) and 58.34% in FY2021 (-10.66 pp).
  • The Q2 2026 figure marks the lowest quarterly EBITDA Margin in data going back to Q1 2020.
  • Compared with a year earlier, EBITDA Margin was higher in four of the last eight quarters, with an average year-over-year change of -20.91 percentage points.
  • The best year-over-year quarter for EBITDA Margin over five years was Q4 2025 (a gain of 1141.73 percentage points); the worst was Q2 2026 (a drop of 1118.57 percentage points).
  • Per Business Quant data, ABCL's EBITDA Margin in the three quarters before Q2 2026 was -609.51% (Q1 2026), -50.17% (Q4 2025) and -793.28% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 653.54 Bn 572.07 Bn 17.26 Bn 35.95%
2 AbbVie 467.01 Bn 440.17 Bn 12.70 Bn 49.01%
3 Merck 367.16 Bn 321.59 Bn 12.21 Bn 6.02%
4 Novartis Ag 277.56 Bn 233.43 Bn 11.24 Bn -
5 Astrazeneca 258.23 Bn 231.79 Bn 12.86 Bn 33.11%
6 Amgen 224.14 Bn 179.54 Bn 7.24 Bn 46.01%
7 Gilead Sciences 187.30 Bn 161.42 Bn 6.22 Bn -124.26%
8 Pfizer 163.47 Bn 110.41 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.31 Bn 105.31 Bn 2.84 Bn 39.10%
10 AbCellera Biologics 3.89 Bn 3.89 Bn - -1,376.44%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1,376.44%
Mar 31, 2026 -609.51%
Dec 31, 2025 -50.17%
Sep 30, 2025 -793.28%
Jun 30, 2025 -257.88%
Mar 31, 2025 -1,353.70%
Dec 31, 2024 -1,191.90%
Sep 30, 2024 -872.57%
Jun 30, 2024 -778.10%
Mar 31, 2024 -502.36%
Dec 31, 2023 -637.34%
Sep 30, 2023 -744.34%
Jun 30, 2023 -454.76%
Mar 31, 2023 -486.53%
Dec 31, 2022 -111.13%
Sep 30, 2022 42.28%
Jun 30, 2022 -7.60%
Mar 31, 2022 72.32%
Dec 31, 2021 61.35%
Sep 30, 2021 -442.88%
API Access

AbCellera Biologics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ABCL&period=max&api_key=YOUR_API_KEY